Have your patients started asking you about psychedelic medicine?
The Psychedelic Medicine Association educates clinicians and provides informational tools so that you can feel confident discussing psychedelic medicine with your patients.
Patients have suffered long enough with therapeutic options that bring little relief. It’s time we explore this new world of options so we can begin helping them truly heal.
The research can’t be denied:
- After MDMA-assisted psychotherapy, 68% of subjects with PTSD no longer qualified for the condition at one-year follow-up
- Ketamine has shown rapid antidepressant and anti-suicidal ideation effects
- Psilocybin has demonstrated improvements in major depression and end-of-life anxiety
These findings are just the beginning. New research findings are coming out regularly that support the use of psychedelic medicines for several difficult-to-treat mental and physical conditions.
The Psychedelic Medicine Association has created a course to help get you up to speed with a psychedelic medicine that's rapidly growing in legal use: psilocybin.
CME/CE ACCREDITED COURSE
Managing Medical Risk In Patients Seeking Psilocybin Therapy
We are excited to offer a CME/CE accredited course to provide healthcare professionals with the tools they need to safely, effectively, and comfortably assess and discuss the relevant medical risks with their patients.
In this course, you will:
- Gain a basic understanding of what psilocybin and psilocybin mushrooms are and their historical use
- Identify the indications for which psilocybin has been researched
- Understand the contraindications of psilocybin therapy and how psilocybin affects the mind and body
- Understand psilocybin’s pharmacology and drug-drug interactions
Memberships
Become a member of The Psychedelic Medicine Association to gain access to a variety of educational and informational tools to help you feel confident to discuss psychedelic medicines with your patients. As a member, you’ll also be connected with like-minded health professionals and the organizations shaping the psychedelic industry.